XML 55 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 2 Months Ended 12 Months Ended
Mar. 31, 2014
Mar. 31, 2015
Jan. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $ (710,608) $ (1,347,957) $ (4,558,874)
Adjustments to reconcile net loss to net cash used in operating activities:      
Provision for doubtful accounts 0 64,811 0
Depreciation and amortization expense 5,765 334,434 31,361
Gain on extinguishment of debt (23,000) 0 (24,783)
Gain on sale of marketable securities 0 (49,791) 0
Deferred income taxes 4,954 (51,922) 0
Stock-based compensation expense 60,187 1,258,848 2,157,857
Amortization of financing costs 25,965 121,578 255,396
Amortization of debt discount 19,406 400,394 136,751
Change in fair value of warrant and conversion feature liability 0 (833,545) 0
Changes in assets and liabilities:      
Accounts receivable 1,128 (912,205) 72,916
Other receivable 0 (188,236) 0
Due from affiliates (22,442) 55,358 4,049
Prepaid expenses and advances 11,342 (118,054) 19,084
Other assets (2,952) (106,510) (27,700)
Accounts payable and accrued liabilities 621,360 851,277 455,738
Medical liabilities 0 249,610 0
Net cash used in operating activities (8,895) (271,910) (1,478,205)
CASH FLOWS FROM INVESTING ACTIVITIES:      
Acquisitions, net of $660,893 of cash and cash equivalents acquired during the year ended March 31, 2015 0 (3,356,145) (250,000)
Increase in cash on consolidation of variable interest entity 0 271,395 0
Proceeds from sale of marketable securities 0 438,884 0
Property and equipment acquired (12,228) (44,509) (22,931)
Increase in restricted cash 0 (510,000) 0
Net cash used in investing activities (12,228) (3,200,375) (272,931)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from issuance of convertible note payable 0 2,000,000 220,000
Proceeds from line of credit 7,000,000 1,000,000 2,811,878
Proceeds from issuance of common stock 2,000,000 0 730,000
Principal payments on notes payable 0 (936,083) (530,000)
Payment of line of credit payable (2,811,878) 0 0
Payment of medical clinic acquisition notes payable (256,000) 0 0
Payments in connection with convertible note redemption (98,252) 0 (707,911)
Contributions by non-controlling interest 0 725,278 0
Distributions to non-controlling interest shareholder (200,000) (600,000) (240,000)
Debt issuance costs (232,676) (533,646) (258,151)
Repurchase of common stock 0 (500) 0
Net cash provided by financing activities 5,401,194 1,655,049 2,025,816
NET (DECREASE) INCREASE IN CASH & CASH EQUIVALENTS 5,380,071 (1,817,236) 274,680
CASH & CASH EQUIVALENTS, BEGINNING OF PERIOD 1,451,407 6,831,478 1,176,727
CASH & CASH EQUIVALENTS, END OF PERIOD 6,831,478 5,014,242 1,451,407
SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION      
Interest paid 84,720 768,845 247,465
Income taxes paid 3,824 32,197 19,513
Non-Cash Financing Activities:      
Convertible note warrant 0 487,620 50,936
Convertible note conversion feature 0 578,155 0
Acquisition related warrant consideration 0 132,000 0
Acquisition related consideration fair value of units issued by consolidated subsidiary 0 274,148 0
Acquisition related deferred tax liability 0 218,183 0
Pre-acquisition net equity of non-controlling interest in variable interest entity 0 191,154 0
NNA term loan discount 1,254,363 0 0
Shares issued in connection with convertible notes redemption 51,748 0 864,298
Fair value of warrant liabilities 2,354,624 0 0
NNA shares issuance discount 1,100,261 0 0
Shares issuable and issued for deferred financing costs 0 0 45,000
Notes payable issued in connection with medical clinic acquisitions 0 0 299,900
Settlement of stock issuable liability with issuance of shares 0 0 159,334
Fair value of embedded conversion feature reacquired in connection with convertible notes redemption $ 0 $ 0 $ 509,890